Details of the Drug

General Information of Drug (ID: DMTXCUS)

Drug Name
Galiximab
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 2 [1]
Drug Type
Antibody
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 13 - 24 days [2]
Cross-matching ID
DrugBank ID
DB04901
TTD ID
D0P2SI

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Activation B7-1 antigen (CD80) TTFZDNP CD80_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Lymphoma
ICD Disease Classification 2A80-2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Activation B7-1 antigen (CD80) DTT CD80 6.87E-07 -0.12 -0.3
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00516217) Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma. U.S. National Institutes of Health.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8.